RxDoctor Payments Data

Steven Tolkan, MD

Nephrology · Napa, CANPI 1871554766

Payments from drug & device makers

$2,147in general payments, 2019–2025

Across 57 payments — averaging $37.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$683
  • Amgen$500
  • Vifor Pharma, Inc.$230
  • Baxter Healthcare$135
  • Otsuka America Pharmaceutical, Inc.$101
  • Akebia Therapeutics Inc$71
  • plus $427 from 11 others

What the payments were for

  • Food & beverage$2,139100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,147 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$153,623
Medicare patients
74
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate14$23,389
Sevelamer Carbonate60$19,214
JardianceEmpagliflozin19$12,476
EliquisApixaban15$11,321
Febuxostat13$2,705
Calcium Acetate19$2,497
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$1,465
Cinacalcet Hcl13$841
Bumetanide13$676
Gabapentin26$643
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$440
Methadone Hcl19$416
Calcitriol32$415
Losartan Potassium76$409
Lidocaine-PrilocaineLidocaine/Prilocaine13$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$71$23,38914 claims
Boehringer IngelheimJardiance$65$12,47619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,341 nephrology providers in California.

Other nephrology in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →